Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: Basal contents and effects of psychotropic medications

14Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Cyclin-dependent kinase-5 (CDK5) and p35/p25 activators, interacting with the exocytotic machinery (e.g. munc18-1 and syntaxin-1A), play critical roles in neurosecretion. The basal status of CDK5/p35/p25 and the effect of psychotropic drugs (detected in blood/urine samples) were investigated in post-mortem prefrontal cortex (PFC)/Brodmann's area 9 of schizophrenia (SZ) and major depression (MD) subjects. In SZ (all subjects, n=24), CDK5 and p35, but not p25, were reduced (-28 to-58%) compared to controls. In SZ antipsychotic-free (n=12), activator p35 was decreased (-52%). In SZ antipsychotic-treated (n=12), marked reductions of CDK5 (-47%), p35 (-76%) and p25 (-36%) were quantified. In MD (n=13), including antidepressant-free/treated subgroups, CDK5, p35 and p25 were unaltered. In SZ (n=24), CDK5, p35 or p25 correlated with munc18-1a, but not with syntaxin-1A. The results demonstrate reduced p35 basal content and down-regulation of CDK5/p35/p25 by antipsychotics in SZ. The suggested CDK5/munc18-1a functional interaction may lead to dysregulated neurosecretion in SZ PFC. © 2012 CINP.

Cite

CITATION STYLE

APA

Ramos-Miguel, A., Javier Meana, J., & García-Sevilla, J. A. (2013). Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: Basal contents and effects of psychotropic medications. International Journal of Neuropsychopharmacology, 16(3), 683–689. https://doi.org/10.1017/S1461145712000879

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free